Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program initiated on February 6, 2024. As part of a larger 12-month buyback plan worth up to DKK 20 billion, the company has been actively purchasing B shares. From February 6 to April 30, 2024, Novo Nordisk is set to repurchase B shares for up to DKK 2.1 billion. Recent transactions, as of the last announcement on March 25, 2024, show that the company has acquired an additional 120,000 B shares at an average price of approximately DKK 888.12, amounting to a total value of DKK 107,504,826. This brings the total repurchased under the program to 1,550,500 B shares at an average price of DKK 863.73 each, totaling DKK 1,339,209,427. Novo Nordisk now holds 48,091,207 B shares as treasury shares, which is 1.1% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. Novo Nordisk's commitment to defeating serious chronic diseases is underscored by its extensive global presence, with approximately 63,400 employees in 80 countries and product availability in around 170 countries.

Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program initiated on February 6, 2024. As part of a larger 12-month buyback plan worth up to DKK 20 billion, the company has been actively purchasing B shares. From February 6 to April 30, 2024, Novo Nordisk is set to repurchase B shares for up to DKK 2.1 billion. Recent transactions, as of the last announcement on March 25, 2024, show that the company has acquired an additional 120,000 B shares at an average price of approximately DKK 888.12, amounting to a total value of DKK 107,504,826. This brings the total repurchased under the program to 1,550,500 B shares at an average price of DKK 863.73 each, totaling DKK 1,339,209,427. Novo Nordisk now holds 48,091,207 B shares as treasury shares, which is 1.1% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. Novo Nordisk's commitment to defeating serious chronic diseases is underscored by its extensive global presence, with approximately 63,400 employees in 80 countries and product availability in around 170 countries.